An overview of vaccine development for COVID-19

Seyed H Shahcheraghi, Jamshid Ayatollahi, Alaa Aa Aljabali, Madhur D Shastri, Shakti D Shukla, Dinesh K Chellappan, Niraj K Jha, Krishnan Anand, Naresh K Katari, Meenu Mehta, Saurabh Satija, Harish Dureja, Vijay Mishra, Abdulmajeed G Almutary, Abdullah M Alnuqaydan, Nitin Charbe, Parteek Prasher, Gaurav Gupta, Kamal Dua, Marzieh LotfiHamid A Bakshi, Murtaza M Tambuwala

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)
267 Downloads (Pure)


The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.
Original languageEnglish
Pages (from-to)235-244
Number of pages10
JournalTherapeutic Delivery
Issue number3
Early online date24 Feb 2021
Publication statusPublished (in print/issue) - 24 Feb 2021

Bibliographical note

Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.


  • COVID-19
  • COVID-19 vaccines
  • SARS-CoV-2


Dive into the research topics of 'An overview of vaccine development for COVID-19'. Together they form a unique fingerprint.

Cite this